2002 Results
Sort By:
Published on June 21, 2016
Cancer Moonshot 2020, a comprehensive cancer collaboration of pharmaceutical and biotech companies, academic cancer centers, community oncologists, and communications technology companies, has announced the formation of the melanoma and sarcoma working group with the goal of speeding promising immunotherapies to clinical trials. The working group will be chaired by Richard…
Published on June 20, 2016
New research aimed at mapping the molecular mechanisms behind the early stages of bladder cancer has discovered that tumors of the disease can be divided into three primary classes, each with very different molecular and disease developing characteristics. The study's findings—presented by a team of researchers from Aarhus University in…
Published on June 8, 2016
AstraZeneca and Foundation Medicine recently announced a collaboration aimed at developing a companion diagnostic for cancer therapeutic Lynparza, AZ’s first-in-class poly ADP-ribose polymerase (PARP) inhibitor that exploits the DNA damage response (DDR) pathway deficiencies to preferentially kill cancer cells. Lynparza is currently approved by the FDA for BRCA-mutated advanced ovarian…
Published on June 7, 2016
It is often said that “the proof is in the pudding” and clinical research is no exception. For years, scientists and physicians have postulated that personalized therapeutic approaches hold the key to efficiently thwarting diseases like cancer. Yet, as a scientific endeavor, researchers are rightfully required to perform due diligence…
Published on June 2, 2016
The results from a unique new pilot program conducted by scientists from the Icahn School of Medicine at Mount Sinai show that multidimensional genomic profiles outperform the targeted cancer panels used currently in many clinical laboratories. The Mt. Sinai team developed and tested the personalized cancer therapy program using an…
Published on June 2, 2016
With $215 million in funding, the federal government’s Precision Medicine Initiative® is expected to generate the scientific evidence needed to move personalized medicine into clinical practice by providing clinicians with the knowledge and tools to determine more precise medical treatment. One objective of the initiative is to accelerate pharmacogenomics (PGx),…
Published on May 31, 2016
DBV Technologies said today it will partner with Nestlé Health Science to develop and commercialize a new diagnostic test for pediatric milk allergy, under a collaboration that could generate up to €100 million (about $112 million) for DBV. The companies will work to create a ready-to-use, standardized atopy patch test for…
Published on May 16, 2016
Canadian researchers have identified a genetic marker that can be detected through a blood test that determines which patients with metastatic colorectal cancer will benefit from receiving the epidermal growth factor receptor (EGFR) inhibitor cetuximab. This new study sheds light on the growing mystery of why cetuximab is ineffective for up…
Published on May 10, 2016
Research teams from 39 institutions around the world collected and analyzed 91 samples of adrenocortical carcinoma (ACC)—hoping to improve our understanding about one of the rarest, and lethal, types of cancer. This comprehensive analysis was performed as part of The Cancer Genome Atlas (TCGA) Research Network. The investigators from this…
Published on May 9, 2016
An international team of researchers has uncovered a multitude of new driver mutations in lung cancer cells that may be responsive to genomically targeted and to immune cell therapies. “We have identified several distinct recurrent mutations that are likely to be recognized by the immune system and therefore would be…
Published on May 4, 2016
The diagnostic work up of most malignant tumors is not complete unless the work up includes genomic characterization. At the time of diagnosis this may consist of a panel of prognostic and/or predictive analyses performed using cytogenetics, fluorescence in situ hybridization, standard molecular technologies, and next-generation sequencing (NGS). Whereas genomic…
Published on April 26, 2016
A new research study, led by scientists at St. Jude Children's Research Hospital, has identified a rare genetic variation associated with a dramatically increased risk of severe acute pancreatitis in acute lymphoblastic leukemia (ALL) patients treated with the chemotherapy agent asparaginase. Asparaginase is an essential agent used to treat ALL…
Published on April 22, 2016
Human Longevity Inc. (HLI) will sequence and analyze up to 500,000 DNA samples from patients in AstraZeneca clinical trials over 10 years in one of four genomics-focused initiatives announced today by the pharma giant and its global biologics R&D arm MedImmune. The value of the collaboration with HLI and other…
Published on April 15, 2016
The past several years have seen some exciting results for cancer immunotherapy. However, there remains a fundamental lack of understanding of immune system recognition in various cancers. Many large-scale sequencing efforts have added to our collective knowledge base, but too many of these studies have been deficient in comprehensive epidemiological…
Published on April 12, 2016
“Life finds a way,” is the famous line uttered by Jeff Goldblum’s character in the original Jurassic Park film. While the statement is true, it is also unfortunate when it applies to cancer cells. When a targeted therapy blocks a pathway that enables tumors to grow, the cancer cells usually…